Evidence: canine Lyme borreliosis (Borrelia burgdorferi): diagnosis, treatment & prevention (peer-reviewed, Europe PMC)
Source: Europe PMC (Europe PubMed Central) REST search — first-hand peer-reviewed abstract records, pulled 2026-07-24. Query: ("Lyme disease" OR "Borrelia burgdorferi") AND dog AND (treatment OR vaccination OR prevention OR management). The cluster returns 6 first-hand abstracts extracted below (verbatim sentences, each traceable by PMID).
Verified claims (verbatim, substring of saved source)
- PMID 41808193 — Background Both Simparica® and Simparica TRIO® chewable tablets are efficacious within 12 h against existing Ixodes scapularis infestations and within 24 h against re-infestations for 1 month.
- PMID 42150803 — Canine vector-borne diseases (CVBDs) pose a significant threat to dogs and public health.
- PMID PPR1213835 — Lyme disease, caused by Borrelia burgdorferi and transmitted by Ixodes scapularis ticks, remains a significant vector-borne illness in the United States.
- PMID 42115648 — Lyme disease, caused by Borrelia burgdorferi and transmitted by Ixodes scapularis ticks, remains a significant vector-borne illness in the United States.
- PMID 41353540 — Background Borrelia burgdorferi, the causative agent of Lyme disease, is a zoonotic vector-borne pathogen transmitted by various Ixodes tick species.
- PMID 42137223 — A comprehensive synthesis of current evidence on surveillance, prevention and control measures for 25 selected vector-borne diseases (VBDs) affecting animals in the EU is presented here.
Studies (PMID / year / journal / title)
- PMID 41808193 (2026, Parasites & vectors) — Efficacy of Simparica and Simparica TRIO for the prevention of Borrelia burgdorferi by Ixodes scapularis.
- PMID 42150803 (2026, Veterinary parasitology, regional studies and reports) — Canine vector-borne diseases in Lebanon: Unveiling prevalence trends and risk factors for public health and disease control.
- PMID PPR1213835 (2026, ) — A double-blinded, placebo-controlled field trial of an OspA-based oral reservoir targeted vaccine against Borrelia burgdorferi
- PMID 42115648 (2026, NPJ vaccines) — A double-blinded, placebo-controlled field trial of an OspA-based oral reservoir targeted vaccine against Borrelia burgdorferi.
- PMID 41353540 (2025, Parasites & vectors) — Efficacy of Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) and Credelio™ (lotilaner) chewable tablets in the prevention of Borrelia burgdorferi transmission from infected Ixodes scapularis in dogs.
- PMID 42137223 (2026, EFSA journal. European Food Safety Authority) — Knowledge mapping of risk mitigation measures against vector-borne diseases.
Source text: pdf-raw/evidence/pubmed_evidence_canine_lyme_disease_2026-07-24.txt (Europe PMC first-hand abstracts, pulled 2026-07-24).